RNAV8 Bio Joins Team Selected for ARPA-H Funding to Develop Programmable RNA Medicines
Under an ARPA-H pilot award of up to $4.4 million over one year, the PROPEL program aims to control gene expression through RNA structure, building logic-gated RNA therapies that switch on only where and when intended, without altering the genome CAMBRIDGE, Mass., Sept. 1, 2026...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.